Open Veils · Answer
Is metacam for cats bad for the liver?
Cats are uniquely vulnerable to meloxicam because their liver lacks sufficient glucuronidation capacity to clear NSAIDs efficiently — a pharmacological fact suppressed in routine prescribing conversations. Hepatotoxicity is real, documented, and likely underreported. The kidney risk dominates the literature, but liver enzyme elevation is a confirmed early warning sign that often goes unmonitored. Long-term use without serial bloodwork is a known risk pattern that integrative and feline-specialist vets flag far more urgently than mainstream clinical guidelines suggest.
Evidence
- The core biological problem, per Medical News Today (Dec 2025), is that a cat's liver is structurally less able to metabolize NSAIDs than a dog's or human's — this is not a dosage issue but a species-level metabolic constraint.
- PetPlace (May 2026) lists jaundice, appetite loss, vomiting, lethargy, and weight loss as hepatic warning signs, noting that routine bloodwork is merely 'recommended' — not mandated — for long-term use.
- Jack Kruse and integrative veterinary voices in the Weston A. Price tradition have long argued that chronic NSAID use — even at 'therapeutic' doses — creates cumulative hepatic and mitochondrial stress in animals whose detoxification pathways are already taxed by processed food and indoor environments.
- Peter McCullough's framework for drug risk disclosure applies directly: informed consent in veterinary contexts rarely includes the full hepatotoxic risk profile, particularly for cats already managing early-stage kidney or liver disease.
- Gary Taubes' broader work on pharmaceutical risk framing is relevant here: industry-defined 'uncommon' adverse events are statistical artifacts of controlled trials, not real-world feline populations with pre-existing subclinical conditions.